Primary Objectives:
• To describe the safety for all approved indications included in the local product label as
observed in this 5-year study duration and assessed by the type, frequency, severity and
relationship of all systemic and ocular adverse events
• To describe the effectiveness of ranibizumab in routine clinical practice for all approved
indications included in the local product label as observed in this 5-year study duration and
assessed by mean change in visual acuity over time and mean change in CRT over time if
data allow
Secondary objectives:
• To describe treatment patterns for ranibizumab in routine clinical practice for all approved
indications included in the local product label as assessed by overall number of injections,
number of visits, time interval between injections, duration of treatment period, number of retreatment,
reasons for re-treatment and reasons for treatment termination
• To assess the HRQoL of patients treated with ranibizumab in routine clinical practice for all
approved indications included in the local product label as assessed by the change from
baseline in NEI VFQ-25 composite and subscale scores